NFM-08. SAFETY AND EFFICACY OF TRAMETINIB IN THE MANAGEMENT OF CHILDREN WITH RASOPATHIES

BACKGROUND: There is emerging evidence regarding the efficacy of agents targeting the MAPK pathway in children with RASopathies. We report our experience with the use of trametinib, a MEK inhibitor, in this population. METHODS: Three patients with neurofibromatosis type 1 (NF-1) and plexiform neurof...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Bavle, Abhishek, Choudhry, Farooq, Gavula, Theresa, Shah, Rikin, Ruiz-Elizalde, Alejandro, Taylor, Ashley, Gross, Naina, Peterson, Jo Elle, Fung, Kar-Ming, McNall-Knapp, Rene
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2018
Gaiak:
Abstracts
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012195/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.516
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak